Click on headlines below to download research

Termination of coverage
Termination of coverage - SymBio Pharmaceuticals | 29/04/2022

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH…

The first whole quarter of internal SymBio sales
SymBio Pharmaceuticals | 27/05/2021

SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the product…

Treakisym approved for DLBCL
SymBio Pharmaceuticals | 30/03/2021

SymBio announced on 23 March 2021 that it has received marketing approval for Treakisym (bendamustine) for diffuse large B-cell lymphoma (DLBCL). The drug…